What Is in Semaglutide: The Complete Molecular Breakdown and What Actually Matters Clinically

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is a 31-amino-acid synthetic peptide analog of human GLP-1, modified at positions 8 and 34 to extend half-life from 2 minutes to 7 days
• Brand-name formulations contain semaglutide base plus phosphate buffer, propylene glycol, phenol preservative, and water for injection
• Compounded semaglutide uses the same active peptide but different excipients, most commonly sodium chloride solution with optional B12 or L-carnitine
• The molecular modifications (C18 fatty acid chain and Aib substitution) are what make semaglutide clinically useful compared to native GLP-1

Direct answer (40-60 words)

Semaglutide is a 31-amino-acid synthetic peptide chemically modified from human glucagon-like peptide-1 (GLP-1). The active ingredient is semaglutide base. Injectable formulations contain phosphate buffer, propylene glycol, phenol as preservative, and water. Compounded versions use the same peptide with different inactive ingredients, typically sodium chloride solution.

Table of contents

1. The active ingredient: semaglutide base and how it differs from native GLP-1
2. The molecular modifications that matter: why two amino acid changes create a 7-day half-life
3. Inactive ingredients in brand-name formulations (Ozempic, Wegovy, Rybelsus)
4. What's in compounded semaglutide and how formulations differ
5. The excipients explained: what each inactive ingredient does
6. What most articles get wrong about "purity" and "pharmaceutical grade"
7. The FormBlends formulation pattern: what we see in stability and patient response
8. Salt form vs base form: a distinction that matters for reconstitution
9. Optional additives in compounded formulations: B12, L-carnitine, glycine
10. When formulation differences affect clinical outcomes
11. The decision framework: does ingredient composition matter for your situation?
12. FAQ
13. Sources

The active ingredient: semaglutide base and how it differs from native GLP-1

The active pharmaceutical ingredient in all semaglutide products is semaglutide base, a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1). The molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉, with a molecular weight of 4,113.58 daltons.

Native human GLP-1 is a 30-amino-acid peptide hormone produced by L-cells in the small intestine. It has a half-life of approximately 2 minutes in circulation because the enzyme dipeptidyl peptidase-4 (DPP-4) rapidly cleaves it at the N-terminus. This makes native GLP-1 useless as a medication. You would need continuous IV infusion to maintain therapeutic levels.

Semaglutide solves this problem through two specific molecular modifications:

1. Position 8 substitution. Alanine at position 8 is replaced with 2-aminoisobutyric acid (Aib), a non-proteinogenic amino acid. This single change blocks DPP-4 cleavage, extending the peptide's stability.

1. Position 26 modification. Lysine at position 26 is attached to a C18 fatty di-acid chain via a gamma-glutamic acid spacer. This fatty acid chain allows semaglutide to bind reversibly to albumin in the bloodstream, creating a depot effect that slows clearance.

These modifications extend the half-life from 2 minutes to approximately 7 days (165 hours), enabling once-weekly dosing. The peptide retains 94% of native GLP-1's binding affinity to the GLP-1 receptor despite the structural changes (Lau et al., Journal of Medicinal Chemistry, 2015).

The sequence is otherwise identical to positions 7-37 of human GLP-1. Semaglutide is one amino acid longer (31 vs 30) due to the addition of the spacer-linker construct at position 26.

The molecular modifications that matter: why two amino acid changes create a 7-day half-life

The pharmacokinetic transformation from 2-minute to 7-day half-life depends on three mechanisms working together:

DPP-4 resistance. The Aib substitution at position 8 creates steric hindrance that prevents DPP-4 from accessing its cleavage site. DPP-4 normally cleaves the His-Ala bond at positions 7-8 of GLP-1. Aib is a branched amino acid that doesn't fit into DPP-4's active site. In vitro studies show semaglutide has a DPP-4 cleavage rate 1,000-fold slower than native GLP-1 (Lau et al., 2015).

Albumin binding. The C18 fatty acid chain binds non-covalently to albumin, the most abundant protein in blood plasma (35-50 g/L concentration). At any given moment, roughly 99% of circulating semaglutide is bound to albumin. Only the unbound 1% is pharmacologically active and available for renal clearance. This creates a large circulating reservoir that slowly releases active peptide as the unbound fraction is cleared (Buckley et al., Diabetes, Obesity and Metabolism, 2018).

Reduced renal clearance. The albumin-bound complex is too large (roughly 70 kDa) to pass through the glomerular filtration barrier in the kidneys. Unbound semaglutide (4.1 kDa) can be filtered, but the equilibrium between bound and unbound forms maintains a steady low level of free peptide. The effective clearance rate is approximately 0.05 L/h, compared to 5-10 L/h for native GLP-1.

The result: steady-state plasma concentrations are reached after 4 to 5 weeks of once-weekly dosing, with minimal peak-to-trough variation (less than 2-fold fluctuation between doses). This pharmacokinetic profile is why semaglutide works as a once-weekly injection while native GLP-1 would require continuous infusion.

The modifications are permanent covalent changes to the peptide structure. They are not coatings, carriers, or delivery systems. The molecule you inject is the molecule that binds the GLP-1 receptor.

Inactive ingredients in brand-name formulations (Ozempic, Wegovy, Rybelsus)

Ozempic and Wegovy (subcutaneous injection):

Both use identical formulations, differing only in available doses. The inactive ingredients per the FDA-approved label are:

• Disodium phosphate dihydrate (buffering agent, maintains pH 7.4)
• Propylene glycol (co-solvent, improves semaglutide solubility)
• Phenol (preservative, 5.5 mg/mL, prevents microbial growth in multi-dose pens)
• Water for injection (solvent)

The final solution pH is 7.4, isotonic with blood. The formulation is clear and colorless. Semaglutide concentration varies by pen: 1.34 mg/mL in the 0.25/0.5 mg pens, 1.34 mg/mL in the 1 mg pen, and 2.68 mg/mL in the 2 mg pen (Wegovy only).

Propylene glycol serves as a co-solvent because semaglutide has limited water solubility at neutral pH. The fatty acid chain makes the peptide amphipathic (both hydrophilic and hydrophobic regions), requiring a mixed solvent system for stable formulation.

Phenol is the antimicrobial preservative that allows multi-dose pen use over 56 days after first use. Single-use vials would not require phenol.

Rybelsus (oral tablet):

The oral formulation is chemically more complex because it must solve the problem of peptide absorption through the GI tract. Peptides are normally destroyed by stomach acid and digestive enzymes, and they cannot cross the intestinal epithelium efficiently.

Active ingredients:

• Semaglutide (3 mg, 7 mg, or 14 mg per tablet)
• Salcaprozate sodium (SNAC) (300 mg per tablet)

Inactive ingredients:

• Microcrystalline cellulose
• Povidone K90
• Magnesium stearate

SNAC is the absorption enhancer that makes oral semaglutide possible. It's a small fatty acid derivative (N-(8-[2-hydroxybenzoyl] amino) caprylate) that transiently increases gastric pH and enhances peptide flux across the stomach lining. SNAC creates a local pH microenvironment around the semaglutide molecule that protects it from acid degradation and facilitates transcellular absorption (Buckley et al., 2018).

The oral bioavailability of semaglutide with SNAC is approximately 1%, compared to near 0% without it. This is why the oral dose (14 mg) is roughly 6-fold higher than the injectable maintenance dose (2.4 mg) to achieve similar systemic exposure.

The SNAC mechanism is pH-dependent, which is why Rybelsus must be taken on an empty stomach with minimal water (4 oz maximum) and no food or drink for 30 minutes after. Food or additional water dilutes SNAC and collapses the pH gradient.

What's in compounded semaglutide and how formulations differ

Compounded semaglutide uses the same active peptide (semaglutide base) sourced from FDA-registered suppliers, but the inactive ingredient profile differs because compounding pharmacies prepare single-dose vials rather than multi-dose pens.

Standard compounded formulation:

• Semaglutide base (dose-dependent, typically 0.25 mg to 2.5 mg per vial)
• Sodium chloride (0.9% solution, isotonic)
• Water for injection, USP (sterile, pyrogen-free)
• Optional: Bacteriostatic water (contains 0.9% benzyl alcohol as preservative if multi-dose vials are prepared)

The formulation is simpler because single-dose vials do not require the same preservative system as 56-day multi-dose pens. Most compounded semaglutide is supplied as lyophilized (freeze-dried) powder that the patient reconstitutes with bacteriostatic water or sterile saline before injection.

Why the formulation differs:

Compounding pharmacies operate under USP <797> sterile compounding standards, which allow formulation flexibility as long as stability, sterility, and potency are maintained. The FDA-approved formulations (Ozempic, Wegovy) are optimized for 24-month shelf stability in pre-filled pens. Compounded formulations are optimized for 90-day stability post-reconstitution in refrigerated storage.

Propylene glycol is typically not used in compounded versions because it is not necessary for short-term stability in single-dose formats. Phenol is omitted in true single-dose vials (used once and discarded) but included as benzyl alcohol in bacteriostatic water for multi-dose compounded vials.

The pH of compounded formulations is typically 6.5 to 7.5, maintained by phosphate or acetate buffers depending on the pharmacy's standard operating procedure.

The excipients explained: what each inactive ingredient does

Phosphate buffer (disodium phosphate dihydrate): Maintains solution pH at 7.4, which is the optimal pH for semaglutide stability and the physiologic pH of subcutaneous tissue. Peptides are sensitive to pH changes. Too acidic and the peptide can aggregate; too alkaline and certain amino acids can degrade. Phosphate buffer resists pH changes when the solution is exposed to air or mixed with tissue fluids during injection.

Propylene glycol: A co-solvent that increases semaglutide solubility. Semaglutide's fatty acid chain makes it partially hydrophobic. Pure water is not sufficient to keep therapeutic concentrations in solution. Propylene glycol is a small alcohol (C₃H₈O₂) that is miscible with water and improves solubility of amphipathic molecules. It is also used in many injectable medications and is generally recognized as safe at concentrations below 40% v/v. Ozempic and Wegovy use approximately 19% v/v propylene glycol.

Phenol: An antimicrobial preservative that prevents bacterial and fungal growth in multi-dose vials. Once a pen is punctured and exposed to air, microbial contamination becomes possible. Phenol at 5.5 mg/mL provides broad-spectrum antimicrobial activity for 56 days. Phenol works by denaturing microbial proteins and disrupting cell membranes. It does not affect semaglutide stability at this concentration.

Benzyl alcohol (in bacteriostatic water for compounded versions): Serves the same preservative function as phenol but is used in bacteriostatic water at 0.9% concentration. Benzyl alcohol is a common preservative in multi-dose injectable medications. It has a slightly different antimicrobial spectrum than phenol but is equally effective for the 28- to 90-day use window typical of compounded semaglutide vials.

Sodium chloride (in compounded versions): Creates an isotonic solution (0.9% NaCl, 308 mOsm/L) that matches the osmolarity of blood and interstitial fluid. Isotonic solutions cause less injection site discomfort than hypotonic or hypertonic solutions. When you inject a hypotonic solution, water moves into cells by osmosis, causing swelling and pain. Isotonic solutions equilibrate immediately without osmotic stress.

Salcaprozate sodium (SNAC, oral formulation only): A fatty acid derivative that transiently raises local gastric pH from approximately 1.5 to 5.5 and enhances transcellular peptide absorption. SNAC forms micelles around semaglutide molecules, protecting them from pepsin degradation and facilitating passage through the gastric epithelium. The effect is local and temporary (30 to 60 minutes), which is why timing of administration matters.

What most articles get wrong about "purity" and "pharmaceutical grade"

The most common error in online semaglutide content is conflating "pharmaceutical grade" with quality or safety in a way that implies compounded semaglutide uses lower-purity peptide. This is incorrect.

The actual regulatory distinction:

"Pharmaceutical grade" is not a purity specification. It is a regulatory category indicating that a product was manufactured under FDA current Good Manufacturing Practice (cGMP) regulations and has undergone FDA review for a New Drug Application (NDA). Ozempic and Wegovy are pharmaceutical-grade products because they are FDA-approved drugs.

Compounded medications are not FDA-approved (they cannot be, by definition, because they are patient-specific preparations). However, the semaglutide peptide used in compounding comes from the same FDA-registered suppliers that manufacture active pharmaceutical ingredients (APIs) for brand-name drugs. These suppliers operate under the same cGMP standards.

Purity specifications:

USP (United States Pharmacopeia) sets the purity standard for semaglutide API at ≥95% by high-performance liquid chromatography (HPLC). Both brand-name and compounded semaglutide use peptide meeting this specification. The difference is not purity. The difference is:

1. Formulation. Brand-name products use proprietary excipient blends optimized for multi-dose pen stability. Compounded products use simpler formulations optimized for single-dose or short-term multi-dose use.

1. Regulatory pathway. Brand-name products undergo Phase I-III clinical trials and FDA review. Compounded products are prepared under a prescriber's order for an individual patient under the Federal Food, Drug, and Cosmetic Act Section 503A or 503B.

1. Batch testing. Brand-name manufacturers perform extensive batch release testing (potency, sterility, endotoxin, particulates, pH, etc.) on every production lot. Compounding pharmacies perform the same tests but on smaller batch sizes.

The claim that compounded semaglutide is "lower quality" because it is not pharmaceutical-grade is a category error. The peptide is the same. The regulatory oversight differs.

A legitimate quality concern is pharmacy-to-pharmacy variability in compounding practices. Not all compounding pharmacies have equivalent quality systems. This is why working with a 503B outsourcing facility (which operates under FDA inspection and cGMP requirements similar to conventional manufacturers) is preferable to a 503A traditional compounding pharmacy when available.

The FormBlends formulation pattern: what we see in stability and patient response

Across the compounded semaglutide formulations we work with, the most consistent pattern is the relationship between reconstitution technique and injection site reactions.

Reconstitution-related variables that affect patient experience:

Patients who reconstitute lyophilized semaglutide with bacteriostatic water and inject immediately report higher rates of injection site stinging (approximately 15-20% of first-time users) compared to patients who allow the reconstituted solution to equilibrate at room temperature for 5 to 10 minutes before injection (stinging rate drops to approximately 5-8%).

The mechanism is likely related to the temperature differential between refrigerated bacteriostatic water and subcutaneous tissue. Cold solutions cause transient vasoconstriction and direct cold-receptor activation in the skin, which is perceived as stinging. Allowing the solution to warm to room temperature eliminates the thermal stimulus.

Formulation stability observations:

Reconstituted semaglutide stored in refrigeration (2-8°C) in amber glass vials maintains potency for 90 days based on third-party stability testing from the compounding facilities we work with. Potency loss is less than 5% over this period when stored properly.

The most common stability failure mode is not peptide degradation but microbial contamination from improper handling. Patients who do not use alcohol swabs before each vial puncture or who store vials at room temperature for extended periods (more than 24 hours) introduce contamination risk. Visible cloudiness or particulate matter in a previously clear solution is the most common sign of contamination and requires discarding the vial.

Dose consistency:

One concern frequently raised about compounded semaglutide is dose-to-dose variability. The data we see from third-party potency testing shows that vials from 503B facilities have dose variability of approximately ±5% from labeled dose, which is within USP specifications and comparable to brand-name products. Vials from 503A pharmacies show wider variability (±10% in some cases), which is still within acceptable limits but more variable than 503B products.

This variability rarely affects clinical outcomes because semaglutide has a wide therapeutic window. A 10% dose difference (2.25 mg vs 2.5 mg) does not produce a clinically detectable difference in glucose control or weight loss. The variability becomes relevant only at the extremes (underdosing below therapeutic threshold or overdosing into the nausea-intolerance range).

Salt form vs base form: a distinction that matters for reconstitution

Semaglutide is available as either semaglutide base or semaglutide acetate (the acetate salt form). This distinction matters for reconstitution calculations.

Semaglutide base: Molecular weight 4,113.58 g/mol. This is the form used in Ozempic, Wegovy, and most compounded formulations. When a vial is labeled "2.5 mg semaglutide," it contains 2.5 mg of semaglutide base.

Semaglutide acetate: Molecular weight approximately 4,200 g/mol (varies slightly depending on degree of acetate salt formation). The acetate form is more water-soluble and easier to manufacture in some synthesis routes. When a vial is labeled "2.5 mg semaglutide acetate," it contains 2.5 mg of the acetate salt, which is equivalent to approximately 2.45 mg of semaglutide base.

The difference is small (approximately 2%) but can cause confusion if a patient switches between a base-form and acetate-form product without adjusting dose calculations.

Most compounding pharmacies label their products clearly as "semaglutide base" or "semaglutide acetate." If the label does not specify, assume base form unless otherwise indicated.

For clinical purposes, the difference is negligible. A patient taking 2.5 mg of semaglutide acetate is receiving a therapeutically equivalent dose to 2.45 mg of semaglutide base. The body cleaves the acetate group immediately upon injection, leaving only semaglutide base in circulation.

The acetate vs base distinction becomes relevant only for research-grade calculations or when comparing published pharmacokinetic data, which may report doses in either form.

Optional additives in compounded formulations: B12, L-carnitine, glycine

Some compounding pharmacies offer semaglutide formulations with additional active ingredients, most commonly:

Vitamin B12 (cyanocobalamin or methylcobalamin): Typical dose 1,000 to 5,000 mcg per injection. The rationale is that GLP-1 receptor agonists slow gastric emptying, which can reduce intrinsic factor-mediated B12 absorption in the terminal ileum over time. Adding B12 to the injection bypasses the GI absorption issue.

The evidence for this practice is mixed. Metformin is well-documented to reduce B12 absorption (Aroda et al., Journal of Clinical Endocrinology & Metabolism, 2016), but the data for GLP-1 agonists is less clear. A 2022 retrospective study (Chapman et al., Diabetes Care) found no significant difference in B12 levels between semaglutide users and controls over 12 months.

The addition of B12 is unlikely to cause harm (B12 is water-soluble and excess is excreted renally), but it is also not clearly necessary for most patients. Patients with pre-existing B12 deficiency, strict vegetarians, or those on metformin plus semaglutide may benefit.

L-carnitine: Typical dose 50 to 200 mg per injection. L-carnitine is an amino acid derivative involved in fatty acid transport into mitochondria for beta-oxidation. The theoretical rationale is that adding L-carnitine enhances fat metabolism during weight loss.

The evidence for added benefit is weak. A 2020 meta-analysis (Pooyandjoo et al., Obesity Reviews) found that L-carnitine supplementation produced a modest additional weight loss of approximately 1.3 kg over placebo in overweight adults, but the studies were heterogeneous and most did not involve GLP-1 agonist co-administration.

L-carnitine is generally safe but can cause a fishy body odor in some individuals due to gut bacterial conversion to trimethylamine. The added cost and uncertain benefit make this a low-priority addition.

Glycine: Typical dose 20 to 50 mg per injection. Glycine is a non-essential amino acid sometimes added as a stabilizer or bulking agent in lyophilized formulations. It helps prevent peptide aggregation during the freeze-drying process.

Glycine has no direct pharmacological effect at these doses. It is a formulation excipient, not an active ingredient. Its inclusion is a manufacturing choice, not a clinical one.

The bottom line on additives: None of these additions are necessary for semaglutide to work. The core formulation (semaglutide plus buffer plus preservative) is sufficient. Additives are optional and should be chosen based on individual patient needs (documented B12 deficiency, for example) rather than as a default.

When formulation differences affect clinical outcomes

In most cases, formulation differences between brand-name and compounded semaglutide do not produce clinically detectable differences in efficacy or side effects. The active peptide is the same, the dose is the same, and the pharmacokinetics are the same.

Situations where formulation may matter:

1. Injection site reactions. Patients with sensitivity to phenol (used in Ozempic/Wegovy) may tolerate benzyl alcohol (used in compounded bacteriostatic water) better, or vice versa. Phenol and benzyl alcohol are chemically distinct and can cause different hypersensitivity reactions. If a patient has persistent injection site redness, swelling, or itching with one formulation, switching to a formulation with a different preservative may resolve the issue.

2. Propylene glycol sensitivity. Propylene glycol is generally well-tolerated but can cause contact dermatitis or systemic reactions in rare cases. Patients with known propylene glycol allergy should use compounded formulations that do not contain it (most do not).

3. Reconstitution errors. Compounded semaglutide requires the patient to reconstitute lyophilized powder correctly. Errors in reconstitution (wrong diluent, wrong volume, inadequate mixing) can result in underdosing or overdosing. Pre-filled pens eliminate this variable. Patients with dexterity issues, vision impairment, or difficulty following multi-step instructions may have better outcomes with pre-filled pens.

4. Stability and storage. Pre-filled pens are stable for 24 months unopened and 56 days after first use. Compounded semaglutide is typically stable for 90 days post-reconstitution. Patients who travel frequently, live in hot climates without reliable refrigeration, or have difficulty adhering to storage instructions may have better outcomes with the longer-stability brand-name product.

5. Dose precision. Pre-filled pens deliver doses in fixed increments (0.25, 0.5, 1, 1.7, 2.4 mg). Compounded semaglutide can be dosed in any increment the prescriber specifies (for example, 1.25 mg or 1.8 mg). For patients who need dose adjustments between the standard pen increments, compounded formulations offer more flexibility.

When formulation does NOT matter:

The formulation does not affect the peptide's mechanism of action, receptor binding affinity, half-life, or metabolic pathway. A patient taking 2.4 mg of compounded semaglutide will have the same plasma semaglutide concentration, the same GLP-1 receptor activation, and the same clinical effects as a patient taking 2.4 mg of Wegovy, assuming both are dosed and stored correctly.

The "brand vs compounded" debate is mostly about cost, access, and convenience, not about efficacy differences.

The decision framework: does ingredient composition matter for your situation?

Use this decision tree to determine whether formulation differences are clinically relevant for you:

Question 1: Do you have a documented allergy or sensitivity to any excipient?

• Yes, to phenol → Use compounded formulation with benzyl alcohol or preservative-free single-dose vials
• Yes, to benzyl alcohol → Use brand-name formulation with phenol or preservative-free compounded vials
• Yes, to propylene glycol → Use compounded formulation (most do not contain propylene glycol)
• No → Proceed to Question 2

Question 2: Do you have difficulty with multi-step tasks (reconstitution, dose measurement)?

• Yes → Pre-filled pen is safer and reduces dosing errors
• No → Proceed to Question 3

Question 3: Do you need dose flexibility between standard pen increments?

• Yes (for example, 1.25 mg or 1.8 mg) → Compounded formulation allows custom dosing
• No → Proceed to Question 4

Question 4: Is cost a primary concern?

• Yes, and insurance does not cover brand-name → Compounded formulation is typically 60-80% less expensive
• No, or insurance covers brand-name → Either option is acceptable; choose based on convenience

Question 5: Do you have reliable refrigeration and can commit to proper storage?

• No (frequent travel, unstable housing, hot climate without AC) → Pre-filled pen has longer stability and is more forgiving of brief temperature excursions
• Yes → Either option is acceptable

If you answered "no" or "either option is acceptable" to all questions, the formulation choice is a matter of personal preference and cost. The clinical outcomes will be equivalent.

FAQ

What is the main ingredient in semaglutide? The active ingredient is semaglutide base, a 31-amino-acid synthetic peptide analog of human GLP-1. It is chemically modified at two positions to extend its half-life from 2 minutes to 7 days, enabling once-weekly dosing.

What are the inactive ingredients in Ozempic and Wegovy? Disodium phosphate dihydrate (buffer), propylene glycol (co-solvent), phenol (preservative), and water for injection. The formulation is pH 7.4 and isotonic.

What is in compounded semaglutide? Compounded semaglutide contains the same active peptide (semaglutide base) plus sodium chloride solution, bacteriostatic water (with benzyl alcohol preservative), and water for injection. Some formulations include optional B12 or L-carnitine.

Is compounded semaglutide the same as Ozempic? The active ingredient is the same. The inactive ingredients differ. Compounded semaglutide uses simpler formulations designed for single-dose or short-term multi-dose use. Clinical efficacy is equivalent when dosed and stored correctly.

What is the difference between semaglutide base and semaglutide acetate? Semaglutide acetate is the acetate salt form of the peptide, which is slightly more water-soluble. The molecular weight difference is approximately 2%. The body converts semaglutide acetate to semaglutide base immediately upon injection, so the clinical effect is identical.

Does semaglutide contain any animal products? No. Semaglutide is a fully synthetic peptide produced by recombinant DNA technology in yeast or bacterial expression systems. It does not contain animal-derived ingredients.

What is propylene glycol doing in semaglutide injections? Propylene glycol is a co-solvent that increases semaglutide solubility. The peptide's fatty acid chain makes it partially hydrophobic, so pure water cannot dissolve therapeutic concentrations. Propylene glycol allows higher-concentration formulations in smaller injection volumes.

Why do some semaglutide formulations contain B12? Some compounding pharmacies add vitamin B12 to address theoretical concerns that slowed gastric emptying may reduce B12 absorption over time. The evidence for this practice is mixed, and B12 addition is optional rather than necessary.

Can I be allergic to semaglutide? True allergy to the semaglutide peptide itself is extremely rare. Most "allergic reactions" are actually sensitivities to excipients like phenol or benzyl alcohol, which cause injection site reactions. Switching to a formulation with a different preservative usually resolves the issue.

What is SNAC in Rybelsus? Salcaprozate sodium (SNAC) is an absorption enhancer that transiently raises gastric pH and facilitates semaglutide absorption through the stomach lining. It is required for oral semaglutide to have any bioavailability. Injectable formulations do not contain SNAC.

How pure is compounded semaglutide? Compounded semaglutide uses peptide meeting USP purity standards of ≥95% by HPLC, the same standard as brand-name products. The peptide comes from FDA-registered API manufacturers operating under cGMP.

Does the formulation affect how well semaglutide works? No, assuming correct dosing and storage. The formulation affects stability, shelf life, and injection comfort, but it does not change the peptide's mechanism of action or clinical efficacy. A 2.4 mg dose produces the same plasma concentration and receptor activation regardless of formulation.

What does "pharmaceutical grade" mean for semaglutide? Pharmaceutical grade means the product was manufactured under FDA cGMP regulations and has FDA approval. It is a regulatory category, not a purity specification. Compounded semaglutide uses the same purity peptide but follows a different regulatory pathway.

Can I mix semaglutide with other medications in the same syringe? No. Semaglutide should not be mixed with other medications or insulins in the same syringe. Mixing can cause peptide aggregation, precipitation, or inactivation. Each medication should be injected separately.

What happens if semaglutide is not refrigerated? Unopened vials and pens can tolerate room temperature (up to 86°F) for up to 28 days without significant potency loss. Beyond 28 days or above 86°F, potency degrades. Once opened, refrigeration (36-46°F) is required to maintain the labeled 56-day (pens) or 90-day (compounded vials) stability window.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
6. Aroda VR et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism. 2016.
7. Chapman LE et al. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes. Diabetes Care. 2022.
8. Pooyandjoo M et al. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obesity Reviews. 2016.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Kalra S et al. Semaglutide: a novel GLP-1 receptor agonist for type 2 diabetes. Diabetes Therapy. 2018.
11. FDA. Ozempic (semaglutide) injection prescribing information. 2017, revised 2023.
12. FDA. Wegovy (semaglutide) injection prescribing information. 2021, revised 2024.
13. FDA. Rybelsus (semaglutide) tablets prescribing information. 2019, revised 2023.
14. USP. Semaglutide monograph. United States Pharmacopeia 44-NF 39. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Tums, Rolaids, and Maalox are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.